Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.

Tamibaro: Full Drug Profile

Medically reviewed by Min Clinic Staff | Updated: January 2026

Tamibaro - General Information

Tamibaro is a novel synthetic retinoid for acute promyelocytic leukaemia (APL). Tamibaro is currently approved in Japan for treatment of recurrent APL, and is undergoing clinical trials in the United States.

 

Pharmacology of Tamibaro

Tamibaro is a new synthetic retinoid drug recently approved for relapsed or refractory acute promyelocytic leukemia (APL) in Japan. It is a specific agonist for retinoic acid receptor alpha/beta. Compared to all-trans retinoic acid (ATRA), a natural retinoid indicated for a first-line treatment of APL, tamibarotene is chemically more stable and several times more potent as an inducer of differentiation in promyelocytic leukemia cells. In contrast to ATRA, whose plasma concentration declines considerably during daily administration, tamibarotene sustains plasma level probably due to a lower affinity for cellular retinoic acid binding protein. Furthermore, adverse side effects were milder than those of ATRA in clinical trials.

 

Additional information about Tamibaro

Tamibaro Indication

Investigated for use/treatment in leukemia (unspecified).

Mechanism Of Action
Tamibaro is a specific agonist for retinoic acid receptor alpha/beta.
Generic Name
Tamibarotene
Synonyms
Am 80; retinobenzoic acid
Drug Category
Anticancer Agents
Drug Type
Small Molecule; Approved; Investigational
Other Brand Names containing Tamibarotene
Amnoid; Tamibaro;
Protein Binding
Over 99%, predominantly to serum albumin.
Chemical IUPAC Name
4-[(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)carbamoyl]benzoic acid
Chemical Formula
C22H25NO3
Organisms Affected
Humans and other mammals